ORPHA:2566
Chronic Epstein-Barr virus infection syndrome
Also known as: CAEBV syndrome · Chronic EBV infection syndrome
Publications
10,261
Trials
0
Interventional, condition-specific
Researchers
88
Distinct authors in sample
Gene link
IRF8
Strong
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Chronic Epstein-Barr virus infection syndrome is a rare infectious disease characterized by familial, primary, chronic Epstein-Barr virus infection which typically manifests with persistent mononucleosis-like signs and symptoms, in the absence of secondary immunodeficiency.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009194
- OMIM:226990
- OMIM:614894
- UMLS:C4751209
Additional Mondo synonyms (7)
IMD32B · IRF8 deficiency, autosomal recessive · chronic EBV infection syndrome · chronic Epstein-Barr virus infection syndrome · immunodeficiency 32B · immunodeficiency 32B, monocyte, Dendritic cell, and natural Killer cell deficiency, autosomal recessive · monocyte and dendritic cell deficiency, autosomal recessive
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Strong — IRF8
- LiteraturePresent
10,261 matched papers (8,161 in last 10 years) Source
- Phenotype characterisedPresent
22 HPO annotations (e.g. Bronchiectasis; Hepatomegaly; Decreased total monocyte count) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (IRF8).
GenCC classification: Strong.
Phenotypes (Monarch / HPO)
22
Associated phenotypes · MONDO:0009194
- Bronchiectasis
- Hepatomegaly
- Decreased total monocyte count
- Pneumonia
- Granulocytic hyperplasia
Showing 5 of 22 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0009194
- DEXAMETHASONE·phase 3
- LENALIDOMIDE·phase 3
- RITUXIMAB·phase 3
- CYCLOPHOSPHAMIDE·phase 1
- FLUDARABINE·phase 1
- TORIPALIMAB·early phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
10,261
10,261 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
10,261 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
8,161 in the last 10 years · low confidence
Phrase hits: 12 · MeSH hits: 0
Who's working on it?
88
Distinct author names in 12 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Li L3 papers · 2023
BGI-Wuhan Clinical Laboratory, BGI-Shenzhen, 430074, Wuhan, China.
Papers in Europe PMC - 02Liu Y2 papers · 2023
Department of Genetics, Jiangxi Maternal and Child Health Hospital, 330006, Nanchang, China.
Papers in Europe PMC - 03Wang L2 papers · 2025
BGI-Wuhan Clinical Laboratory, BGI-Shenzhen, 430074, Wuhan, China.
Papers in Europe PMC - 04Adhikary A1 paper · 2022
Department of Information and Communication Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Papers in Europe PMC - 05Aizawa N1 paper · 2010
Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. n.aizawa@oph.med.tohoku.ac.jp
Papers in Europe PMC - 06Akeno N1 paper · 2025
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Papers in Europe PMC - 07Alomar P1 paper · 1989Papers in Europe PMC
- 08Baratelli E1 paper · 1990Papers in Europe PMC
- 09Broggini M1 paper · 1990Papers in Europe PMC
- 10Buchwald D1 paper · 1988
Department of Medicine, Brigham and Women's Hospital, Boston 02115.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 12 · after dedupe 12 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 12 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (12)
- isrctn·ISRCTN15438979·Recruiting·An early phase trial to test the safety and determine the appropriate dose of BTM-3566 in patients with mature B cell lymphoma and advanced solid tumors
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45104480·Recruiting·A modular, multi-part, multi-arm, open-label, phase I/II study to evaluate the safety and tolerability of GRWD5769 alone and in combination with anticancer treatments in patients with solid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45965456·Suspended·Randomised, open-label international trial with Verapamil alone compared with Verapamil plus another immunotherapy for people with newly diagnosed type 1 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10454031·No longer recruiting·A clinical study in order to compare the effectiveness and safety of two different treatments in patients with newly diagnosed primary immune thrombocytopenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53331091·No longer recruiting·A study to evaluate safety, pharmacokinetics, and activity of cevostamab in patients with relapsed or refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26168155·No longer recruiting·Study evaluating the safety and activity of cevostamab (BFCR4350A) given by subcutaneous injection in participants with relapsed or refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49178226·No longer recruiting·A study evaluating the effects of the body on and the safety and effectiveness of mosunetuzumab in patients with relapsed or refractory follicular lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN95363507·No longer recruiting·Tocilizumab in anti-TNF refractory patients with juvenile idiopathic arthritis (JIA) associated uveitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27438588·No longer recruiting·Early enteral supply of Intestamin® in severe sepsis and its influence on organ dysfunction
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74427627·Stopped·Multi-centre randomised placebo-controlled trial of corticosteroids in the prevention of coronary artery abnormalities in acute Kawasaki Disease (KD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN20573724·Recruiting·A study to assess the safety and efficacy of an experimental malaria vaccine by infecting vaccinated and unvaccinated volunteers with malaria parasites
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN55111436·No longer recruiting·A double-blind randomised trial to compare oral azacitidine (CC-486) with placebo in adults with acute myeloid leukaemia and myelodysplasia who are undergoing allogeneic stem cell transplantation
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Chronic Epstein-Barr virus infection syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Chronic Epstein-Barr virus infection syndrome" OR "CAEBV syndrome" OR "Chronic EBV infection syndrome" OR "IMD32B" OR "IRF8 deficiency, autosomal recessive" OR "immunodeficiency 32B" OR "immunodeficiency 32B, monocyte, Dendritic cell, and natural Killer cell deficiency, autosomal recessive" OR "monocyte and dendritic cell deficiency, autosomal recessive") OR ("IRF8" OR "IRF8 syndrome" OR "IRF8-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Chronic Epstein-Barr virus infection syndrome" OR "CAEBV syndrome" OR "Chronic EBV infection syndrome" OR "IMD32B" OR "IRF8 deficiency, autosomal recessive" OR "immunodeficiency 32B" OR "immunodeficiency 32B, monocyte, Dendritic cell, and natural Killer cell deficiency, autosomal recessive" OR "monocyte and dendritic cell deficiency, autosomal recessive"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (10261) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T20:32:10.270Z
